3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
13
Small Cell Lung Carcinoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Neoplasms
3
Lung Neoplasms
3
Triple Negative Breast Neoplasms
2
Thymoma
2
Squamous Cell Carcinoma of Head and Neck
2
Mesothelioma, Malignant
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Thyroid Neoplasms
1
Ovarian Neoplasms
1
Non-squamous Non-small-cell Lung Cancer
1
Neoplasm Metastasis
1
NSCLC
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Advanced Non-squamous Non-small-cell Lung Cancer
1
Advanced Non-small Cell Lung Cancer
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
7
pembrolizumab
6
Radiotherapy
6
Cisplatin
6
Sunitinib
5
Carboplatin
5
Paclitaxel
4
Thymectomy
3
130-nm albumin-bound paclitaxel
3
selinexor
2
lenvatinib
2
fludarabine
2
Taxes
2
Robotic Surgical Procedures
2
Ramucirumab
2
Prednisone
2
Pemetrexed
2
Octreotide
2
Nivolumab
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
Methylprednisolone
2
Imatinib Mesylate
2
Etoposide
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Doxorubicin
2
Chemoradiotherapy
2
Celecoxib
2
zimberelimab
1
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thymoma
×
lenvatinib
×
Thoracic
×
Clear all
NCT04710628
2026-02-19
PECATI
MedSIR
Phase 2
Completed
43 enrolled
NCT05832827
2023-10-23
Artemis
National Cancer Center, Japan
Phase 2
Recruiting
35 enrolled